Roivant Sciences
ROIV · NASDAQ
$34.92+$0.22 (+0.63%)TodayMarket closed ·
Prev close $34.70
EPS: actual vs estimate
Beat the estimate in 4 of the last 8 quarters, by 65.1% on average
Next report: , before the market opens
- Quarter
- Q2 FY27
- EPS estimate
- -$0.46
- Revenue estimate
- $3.49M
Reported EPS
Estimated EPS
| Quarter | Estimate | Reported | Surprise |
|---|---|---|---|
| Q1 FY27 | -$0.336 | -$0.26 | +22.6% |
| Q4 FY26 | -$0.3523 | -$0.58 | −64.6% |
| Q3 FY26 | -$0.324 | -$0.38 | −17.3% |
| Q2 FY26 | -$0.341 | -$0.17 | +50.1% |
| Q1 FY26 | -$0.3162 | -$0.33 | −4.4% |
| Q4 FY25 | -$0.3142 | -$0.29 | +7.7% |
| Q3 FY25 | -$0.2871 | $0.23 | +180.1% |
| Q2 FY25 | -$0.2614 | -$0.31 | −18.6% |
Earnings calls
- Bank of America Global Healthcare Conference 2026
- Citigroup’s Biopharma Back to School Summit 2026
- 12th Annual Cantor Fitzgerald Global Healthcare Conference
- Wells Fargo 21st Annual Healthcare Conference
- Special Call - Roivant Sciences Ltd.
- Special Call - Roivant Sciences Ltd.
- ROIV - Earnings call Q1 2027
- Goldman Sachs 47th Annual Global Healthcare Conference 2026
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.